Lite Strategy, Inc. (LITS)
1.03
+0.06
(+5.96%)
USD |
NASDAQ |
Nov 06, 10:24
Lite Strategy Enterprise Value : 25.80M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 25.80M |
| November 04, 2026 | 29.29M |
| November 03, 2026 | 28.00M |
| November 02, 2026 | 25.65M |
| October 30, 2026 | 30.59M |
| October 29, 2026 | 32.21M |
| October 28, 2026 | 34.15M |
| October 27, 2026 | 31.72M |
| October 26, 2026 | 30.59M |
| October 23, 2026 | 31.89M |
| October 22, 2026 | 32.86M |
| October 21, 2026 | 34.48M |
| October 20, 2026 | 32.86M |
| October 19, 2026 | 31.89M |
| October 16, 2026 | 31.56M |
| October 15, 2026 | 33.02M |
| October 14, 2026 | 32.21M |
| October 13, 2026 | 33.51M |
| October 12, 2026 | 33.83M |
| October 09, 2026 | 35.45M |
| October 08, 2026 | 33.83M |
| October 07, 2026 | 35.45M |
| October 06, 2026 | 39.99M |
| October 05, 2026 | 39.66M |
| October 02, 2026 | 39.02M |
| Date | Value |
|---|---|
| October 01, 2026 | 38.85M |
| September 30, 2026 | 37.07M |
| September 29, 2026 | 38.85M |
| September 28, 2026 | 38.37M |
| September 25, 2026 | 40.96M |
| September 24, 2026 | 40.64M |
| September 23, 2026 | 32.53M |
| September 22, 2026 | 36.42M |
| September 21, 2026 | 35.78M |
| September 18, 2026 | 30.91M |
| September 17, 2026 | 28.00M |
| September 16, 2026 | 27.35M |
| September 15, 2026 | 29.62M |
| September 14, 2026 | 31.56M |
| September 11, 2026 | 30.27M |
| September 10, 2026 | 28.65M |
| September 09, 2026 | 28.65M |
| September 08, 2026 | 29.94M |
| September 04, 2026 | 31.24M |
| September 03, 2026 | 28.00M |
| September 02, 2026 | 28.00M |
| September 01, 2026 | 26.51M |
| August 31, 2026 | 26.23M |
| August 28, 2026 | 26.07M |
| August 27, 2026 | 26.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group, Inc. | 1.453B |
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.02M |
| Total Expenses (Quarterly) | 13.02M |
| EPS Diluted (Quarterly) | -0.3761 |
| Earnings Yield | -192.9% |
| Normalized Earnings Yield | -81.41 |